Evidence map›Paper›PMID 33115754›Full record

ArticleThe Journal of biological chemistry2020

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.

Shuhei Suzuki, Masashi Okada, Tomomi Sanomachi, Keita Togashi, Shizuka Seino, Atsushi Sato, Masahiro Yamamoto, Chifumi Kitanaka

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Cancer Stem Cells and Their Therapeutic Usage.Advances in experimental medicine and biology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shuhei SuzukiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan; Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan.
Masashi OkadaDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan. Electronic address: m-okada@med.id.yamagata-u.ac.jp.
Tomomi SanomachiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan; Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan.
Keita TogashiDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan; Department of Ophthalmology and Visual Sciences, Yamagata University School of Medicine, Yamagata, Japan.
Shizuka SeinoDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan.
Atsushi SatoDepartment of Neurosurgery, Yamagata University School of Medicine, Yamagata, Japan.
Masahiro YamamotoDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan.
Chifumi KitanakaDepartment of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan; Research Institute for Promotion of Medical Sciences, Faculty of Medicine, Yamagata University, Yamagata, Japan. Electronic address: ckitanak@med.id.yamagata-u.ac.jp.
Yamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative recurrence from microscopic residual disease must be prevented to cure intractable cancers, including pancreatic cancer. Key to this goal is the elimination of cancer stem cells (CSCs) endowed with tumor-initiating capacity and drug resistance. However, current therapeutic strategies capable of accomplishing this are insufficient. Using

Indexed as

AnimalsAntineoplastic Agents, HormonalApoptosisBiomarkers, TumorCell ProliferationDexamethasoneDual Specificity Phosphatase 1Gene Expression Regulation, NeoplasticHumansMaleMAP Kinase Kinase 4MiceMice, Inbred BALB CMice, NudeNeoplastic Stem CellsPancreatic NeoplasmsAntineoplastic Agents, HormonalBiomarkers, TumorDexamethasoneDual Specificity Phosphatase 1DUSP1 protein, humanMAP Kinase Kinase 4anticancer drugcancer stem cellsc-Jun N-terminal kinase (JNK)drug resistanceglucocorticoid receptor

Identifiers

PMID33115754
PMCPMC7939393
OpenAlexW3097956443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.